ERBB2 and cancer: Since HER2+ BBM treatments, including lapatinib, are associated with limited availability and significant cytotoxicity associated with neurological symptoms25, several research groups have developed more targeted therapy using liposomes, polymeric nanoparticles, or polymeric micelles26 to deliver chemotherapeutic drugs directly to cancer cells or cancer tissues20,21,23–25,27–32.